A source close to the matter has stated that NanoViricides (NYSEMKT:NNVC) is in the process of being acquired. "Due to recent developments in the company, we are intent on acquiring it for defensive purposes along with expansion of our drug line-up, among other development based factors. We have valued it between 2.25 and 4.5 billion dollars, although we are yet to reach an agreement."
The source has said that the full details will "hopefully be agreed upon and fully disclosed by the end of this month", and that this acquisition will entail all aspects of the company, its stock, and licenses. The financial promise that this acquisition brings along is uncertain although this valuation is multiple times larger than NanoViricides market cap, but we must keep in mind its market cap may not reflect the value of its licenses and technologies, and whatever this "recent developments" means for the companies valuation. This source has disclosed that they are "unwilling to disclose any further information" due to their key role in the acquisition which may reveal their identity in a still unsigned deal.
I will cover further developments as they arise, if you see any new developments on the news, contact me as I'd like to keep my readers on top of the acquisition.
As always, happy investing! -Matt